🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Azora Therapeutics, Inc. (AZR)
NASDAQ: AZR · Real-Time Price · USD
3.870
+0.070 (1.84%)
At close: Nov 19, 2026, 4:00 PM EST
4.250
+0.380 (9.82%)
After-hours: Nov 19, 2026, 7:55 PM EST

Company Description

Azora Therapeutics, Inc. operates as a biopharmaceutical company that develops small molecule new chemical entities for the treatment of autoimmune and inflammatory diseases.

It offers treatment for dermatology and gastroenterology. The company's pipeline includes AT177, a colon‑targeted aryl hydrocarbon receptor (AhR) agonist to enable localized activation with limited systemic exposure in development for ulcerative colitis.

Azora Therapeutics, Inc. was formerly known as Meya Pharmaceuticals, Inc. and changed its name to Azora Therapeutics, Inc. in March 2019.

The company was incorporated in 2017 and is based in Encino, California.

Azora Therapeutics, Inc.
CountryUnited States
Founded2017
IPO DateJul 30, 2018
IndustryBiotechnology
SectorHealthcare

Contact Details

Address:
4267 Valley Meadow Road
Encino, California 91436
United States
Phone(818) 276-6726
Websiteazoratherapeutics.com

Stock Details

Ticker SymbolAZR
ExchangeNASDAQ
Reporting CurrencyUSD
CIK Code0001513525
CUSIP Number054800107
ISIN NumberUS0548001074
Employer ID80-0667150
SIC Code2834

Key Executives

NamePosition
Dr. Julie Saiki Ph.D.Co-Founder, Treasurer, Secretary and Director

Latest SEC Filings

DateTypeTitle
Nov 17, 2026S-3Registration statement under Securities Act of 1933
Nov 13, 2026S-8Securities to be offered to employees in employee benefit plans
Nov 12, 20268-KCurrent Report
Nov 12, 202610-QQuarterly Report
Nov 9, 20268-KCurrent Report
Nov 3, 2026SCHEDULE 13G/AFiling
Oct 28, 20268-KCurrent Report
Oct 26, 2026EFFECTNotice of Effectiveness
Oct 21, 202610-Q/A[Amend] Quarterly report
Oct 21, 2026S-3/A[Amend] Registration statement under Securities Act of 1933